12 Feb It’s all about timing: CellProthera CEO talks CDMO partnership with CELLforCURE
For some companies, patience may be a virtue when it comes to collaboration.
Press clips
04 Oct Drug TARGET REVIEW: Cell and gene therapy development moves into cardiac indications
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
02 Sep CellProthera inches closer to Phase III trial for heart attack cell therapy
Speaking at a press conference, CellProthera’s CEO said the company is moving into the final phase of clinical development for its product.
31 Aug Euro Health Leaders: Navigating the Challenges of Autologous Cell Therapy Production
Revolutionizing Cardiac Regeneration.
11 Jul CellProthera and BioCardia Collaborate on Phase 2 Trial of ProtheraCytes to Treat AMI
July 8, 2024—France-based CellProthera and BioCardia, Inc., which is headquartered in California, announced findings from the collaborative phase 2 trial of CellProthera’s ProtheraCytes for the treatment of acute myocardial infarction (AMI). Additionally, the companies noted they plan to continue the collaboration into phase 3.
14 Jun Drug Discovery News: A cell therapy to heal a broken heart
Researchers harvest stem cells from patients who have recently had a heart attack and use them to trigger regeneration of their cardiac muscle.
13 Jun Drug Development & Delivery: CellProthera Announces Positive Phase 1/2b Data for ProtheraCytes Cell Therapy in Acute Myocardial Infarction
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell therapy as a promising option to repair and regenerate heart tissue. The data was presented today by Faiez Zannad, MD, PhD, Chairman of the study’s steering committee and emeritus professor of therapeutics at the Université of Lorraine.
16 Apr DDW: 2024 predictions: Experts weigh in on stem cells
DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on the future of stem cells in drug discovery.
16 Apr EUROPEAN PHARMACEUTICAL MANUFACTURER: Optimising TIME-TO-MARKET for innovative cell therapy
Didier HAGUENAUER - CMO - CELLPROTHERA
29 Feb PHARMIWEB: CellProthera collaborates with Japanese stem cell experts…
CellProthera collaborates with Japanese stem cell experts at Shonan-Kamakura General Hospital (SKGH) on clinical manufacturing for upcoming autologous stem cell trials in ischemic diseases